Skip to main content
. 2018 Dec 10;9(24):4762–4773. doi: 10.7150/jca.25138

Table 3.

Anti-tumor activity of XPO1 inhibitors against pancreatic cancer cells (IC50*, M)

KPT-185 KPT-276 KPT-330
SU8686 3.5 x 10-6 6.7 x 10-6 9.2 x 10-7
MiaPaCa2 2.4 x 10-6 1.1 x 10-5 7.2 x 10-7
Panc1 1.1 x 10-6 2.9 x 10-6 1.1 x 10-6
BxPc3 9.6 x 10-6 1.6 x 10-5 1.2 x 10-5
Panc0203 R 2.2 x 10-5 5.6 x 10-6
Panc1005 1.5 x 10-6 1.3 x 10-5 1.3 x 10-6
Panc0813 1.7 x 10-6 2.3 x 10-6 4.1 x 10-7
AsPc1 2.9 x 10-5 R R

Cell lines were cultured with three XPO1 inhibitors for 72 and cell viability was measured by MTT assay. *IC50s were extrapolated from MTT data using Graphpad Prism software as described in Materials and Methods. R: resistant.